{"disease":{"id":"biliary-tract-cancer","name":"Biliary tract cancer","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":15},"drugs":{"marketed":[{"drug_id":"pemigatinib","indication_name":"Biliary tract cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pemazyre","generic_name":"PEMIGATINIB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"Fibroblast growth factor receptor 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":"200","mechanism":"Pemazyre blocks the activity of the FGFR1 protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic biliary tract cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of biliary tract cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"zanidatamab","indication_name":"biliary tract cancer (BTC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ziihera","generic_name":"ZANIDATAMAB","company_name":"Jazz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Bispecific HER2-directed Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Zanidatamab works by binding to two different parts of the HER2 protein, blocking its growth-promoting signals and slowing tumor growth."},{"drug_id":"zanidatamab","indication_name":"biliary tract cancer (BTC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ziihera","generic_name":"ZANIDATAMAB","company_name":"Jazz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Bispecific HER2-directed Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Zanidatamab works by binding to two different parts of the HER2 protein, blocking its growth-promoting signals and slowing tumor growth."},{"drug_id":"ivosidenib","indication_name":"Biliary tract cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tibsovo","generic_name":"IVOSIDENIB","company_name":"Servier","drug_phase":"marketed","molecular_target":"mutant IDH1","drug_class":"Isocitrate Dehydrogenase 1 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Ivosidenib inhibits mutant IDH1, reducing 2-HG levels and promoting myeloid differentiation in AML."}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04731220","title":"A Questionnaire Survey for Biliary Tract Cancers","phase":"","overall_status":"UNKNOWN","enrollment_count":12000,"lead_sponsor_name":"Kyungpook National University Chilgok Hospital","has_results":false},{"nct_id":"NCT06276153","title":"Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT00339560","title":"A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China","phase":"","overall_status":"COMPLETED","enrollment_count":2624,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06139042","title":"Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":1608,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04935853","title":"Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study","phase":"","overall_status":"RECRUITING","enrollment_count":1350,"lead_sponsor_name":"GERCOR - Multidisciplinary Oncology Cooperative Group","has_results":false},{"nct_id":"NCT07221253","title":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04637048","title":"Observational Study on Patients With Hepatobiliary Tumors","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Gang Chen, MD","has_results":false},{"nct_id":"NCT04163900","title":"Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":773,"lead_sponsor_name":"NuCana plc","has_results":true},{"nct_id":"NCT06109779","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":757,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT07101874","title":"A Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC Patients","phase":"","overall_status":"COMPLETED","enrollment_count":729,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04068168","title":"Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)","phase":"","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06467357","title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":620,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03797326","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06975917","title":"Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers (TOG/GI-SAFRADJU-2501)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Ankara University","has_results":false},{"nct_id":"NCT05896956","title":"The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT05184400","title":"Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Herlev and Gentofte Hospital","has_results":false},{"nct_id":"NCT05667350","title":"AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC)","phase":"","overall_status":"UNKNOWN","enrollment_count":492,"lead_sponsor_name":"Eastern Hepatobiliary Surgery Hospital","has_results":false},{"nct_id":"NCT04401709","title":"Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":490,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT04482309","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":477,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05123482","title":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05489211","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":454,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04445532","title":"Hepatobiliary Tumors Tissue Samples Acquisition","phase":"","overall_status":"UNKNOWN","enrollment_count":450,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT04907643","title":"Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT06360354","title":"A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06849193","title":"Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational Study","phase":"","overall_status":"RECRUITING","enrollment_count":332,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT04066491","title":"Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":309,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT07454486","title":"TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT07282262","title":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05775159","title":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":294,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01589328","title":"Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PB","phase":"NA","overall_status":"COMPLETED","enrollment_count":288,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT06282575","title":"Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":286,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT06293898","title":"Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":280,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT06909188","title":"The Study of Association of Helicobacter Infections in Biliary Tract Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Institute of Liver and Biliary Sciences, India","has_results":false},{"nct_id":"NCT02182778","title":"GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":246,"lead_sponsor_name":"Kansai Hepatobiliary Oncology Group","has_results":false},{"nct_id":"NCT04969887","title":"Combination Immunotherapy in Rare Cancers Under InvesTigation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":240,"lead_sponsor_name":"Olivia Newton-John Cancer Research Institute","has_results":false},{"nct_id":"NCT06792435","title":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Evopoint Biosciences Inc.","has_results":false},{"nct_id":"NCT05835778","title":"Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI","phase":"","overall_status":"COMPLETED","enrollment_count":236,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06219941","title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07062263","title":"Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Tata Memorial Centre","has_results":false},{"nct_id":"NCT06428409","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07169916","title":"Yueju Pill Combined With Standard Therapy In Advanced Biliary Tract Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":210,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06662877","title":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":206,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT02992340","title":"Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":204,"lead_sponsor_name":"ASLAN Pharmaceuticals","has_results":false},{"nct_id":"NCT07156058","title":"MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":204,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03631173","title":"Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":201,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT04776837","title":"Predicting Disease Progression and/or Recurrence in Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT07142226","title":"Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"CHA University","has_results":false},{"nct_id":"NCT05520788","title":"Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT04067960","title":"Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":197,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}